{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T20:46:34Z","timestamp":1763498794562},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1097\/01.wnf.0000165351.10841.fa","type":"journal-article","created":{"date-parts":[[2005,6,17]],"date-time":"2005-06-17T08:01:18Z","timestamp":1118995278000},"page":"145-147","source":"Crossref","is-referenced-by-count":30,"title":["Olanzapine-Induced Myoclonic Status"],"prefix":"10.1097","volume":"28","author":[{"given":"Ana","family":"Camacho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Garc\u00eda-Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Villarejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Pomares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210203","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00003495-199753020-00007","article-title":"Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses.","volume":"53","author":"Fulton","year":"1997","journal-title":"Drugs"},{"key":"R2-11-20210203","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1212\/WNL.41.3.369","article-title":"Clozapine-related seizures.","volume":"41","author":"Devinsky","year":"1991","journal-title":"Neurology"},{"key":"R3-11-20210203","first-page":"13","article-title":"Safety of olanzapine.","volume":"58","author":"Beasley","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"R4-11-20210203","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hup.537","article-title":"EEG abnormalities associated with antipsychotics: a comparison of quetiapine, olanzapine, haloperidol and healthy subjects.","volume":"18","author":"Amann","year":"2003","journal-title":"Hum Psychopharmacol"},{"key":"R5-11-20210203","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1176\/appi.ajp.159.1.109","article-title":"EEG abnormalities during treatment with typical and atypical antipsychotics.","volume":"159","author":"Centorrino","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R6-11-20210203","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1192\/bjp.178.1.85-a","article-title":"Lowered seizure threshold on olanzapine.","volume":"178","author":"Woolley","year":"2001","journal-title":"Br J Psychiatry"},{"key":"R7-11-20210203","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1345\/aph.1C288","article-title":"Olanzapine-associated seizure.","volume":"37","author":"Bonelli","year":"2003","journal-title":"Ann Pharmacother"},{"key":"R8-11-20210203","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1345\/aph.17385","article-title":"Seizure associated with olanzapine.","volume":"33","author":"Lee","year":"1999","journal-title":"Ann Pharmacother"},{"key":"R9-11-20210203","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1345\/aph.1A207","article-title":"New-onset seizure associated with quetiapine and olanzapine.","volume":"36","author":"Hedges","year":"2002","journal-title":"Ann Pharmacother"},{"key":"R10-11-20210203","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00004714-200004000-00034","article-title":"Seizures caused by possible interaction between olanzapine and clomipramine.","volume":"20","author":"Deshauer","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"R11-11-20210203","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1345\/aph.18399","article-title":"Fatal status epilepticus associated with olanzapine therapy.","volume":"33","author":"Wyderski","year":"1999","journal-title":"Ann Pharmacother"},{"key":"R12-11-20210203","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0013-4694(94)90070-1","article-title":"Spectrum of EEG abnormalities during clozapine treatment.","volume":"91","author":"Malow","year":"1994","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"R13-11-20210203","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0920-1211(96)00061-7","article-title":"Kindling with clozapine: behavioural and molecular consequences.","volume":"26","author":"Stevens","year":"1996","journal-title":"Epilepsy Res"},{"key":"R14-11-20210203","first-page":"49","article-title":"Toxin and drug-induced myoclonus.","volume":"89","author":"Gordon","year":"2002","journal-title":"Adv Neurol"},{"key":"R15-11-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00023210-200418020-00003","article-title":"Drug-induced myoclonus: frequency, mechanisms and management.","volume":"18","author":"Jimenez-Jimenez","year":"2004","journal-title":"CNS Drugs"},{"key":"R16-11-20210203","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1212\/WNL.36.9.1226","article-title":"Seizures and myoclonus in patients with Alzheimers disease.","volume":"36","author":"Hauser","year":"1986","journal-title":"Neurology"},{"key":"R17-11-20210203","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0924-977X(01)00101-8","article-title":"Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram.","volume":"11","author":"Brosen","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"key":"R18-11-20210203","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1136\/jnnp.66.3.410","article-title":"Convulsions induced by donepezil.","volume":"66","author":"Babic","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R19-11-20210203","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimers disease in nursing care facilities. A double-blind, randomized, placebo-controlled trial.","volume":"57","author":"Street","year":"2000","journal-title":"Arch Gen Psychiatry"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.wnf.0000165351.10841.fa","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T21:44:07Z","timestamp":1620942247000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200505000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.wnf.0000165351.10841.fa","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}